Abstract
The recent discussion about the dangers of using angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARA) in patients with COVID-19 is analyzed in the article. There is controversy over the hypothesis that these drugs can be factors contributing to an unfavorable outcome of a viral disease, as well as the absence of any clinical evidence for this hypothesis. The opinion that withdrawal of ACE inhibitors and ARA in patients with COVID-19 may increase the risk of adverse outcomes is presented.
Highlights
В статье анализируется возникшая в последнее время дискуссия по поводу опасности применения ингибиторов ангиотензинпревращающего фермента и антагонистов рецепторов ангиотензина II (АРА) у больных с COVID-19
The recent discussion about the dangers of using angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor antagonists (ARA) in patients with COVID-19 is analyzed in the article
The opinion that withdrawal of ACE inhibitors and ARA in patients with COVID-19 may increase the risk of adverse outcomes is presented
Summary
В статье анализируется возникшая в последнее время дискуссия по поводу опасности применения ингибиторов ангиотензинпревращающего фермента (иАПФ) и антагонистов рецепторов ангиотензина II (АРА) у больных с COVID-19. Однако, что при всей остроте проблемы COVID-19 показатели смертности от этого заболевания не идут ни в какое сравнение с показателями смертности от сердечно-сосудистых заболеваний (ССЗ), остающихся основной причиной смертности населения. Что пандемия COVID-19 может еще более увеличить смертность от ССЗ.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
